Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race
Zealand Pharma shares plunged Friday, dropping 32.53% to 249.10 Danish crowns by 10:40 a.m. local time. Investors punished the Danish biotech after fresh data on its obesity drug petrelintide disappointed, sending the stock toward a record single-day loss and slashing around 8.3 billion crowns from its market cap.